A Phase Ib Trial of M7824 and Eribulin in Patients With Metastatic Triple Negative Breast Cancer (TNBC)
Latest Information Update: 03 Nov 2022
At a glance
- Drugs Bintrafusp alfa (Primary) ; Eribulin (Primary)
- Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Adverse reactions
Most Recent Events
- 27 Oct 2022 Status changed from completed to discontinued.
- 26 Oct 2022 Status changed from recruiting to completed.
- 22 Sep 2022 Planned End Date changed from 31 Oct 2021 to 31 Oct 2022.